Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H33ClN2O5S |
Molecular Weight | 424.983 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O)[C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl
InChI
InChIKey=KDLRVYVGXIQJDK-AWPVFWJPSA-N
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdfCurator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf
Curator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105985/pdf/ac003014.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/9797245
Curator's Comment: Clindamycin phosphate is the prodrug of clindamycin
with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12860123 |
|||
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN T Approved UseClindamycin Phosphate is indicated in the treatment of acne vulgaris. Launch Date3.31862409E11 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseLower respiratory tract infections including pneumonia, empyema, and lung abscess
caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis),
and Staphylococcus aureus. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSkin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus
aureus, and anaerobes. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseGynecological infections including endometritis, nongonococcal tubo-ovarian abscess,
pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseIntra-abdominal infections including peritonitis and intra-abdominal abscess caused by
susceptible anaerobic organisms. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSepticemia caused by Staphylococcus aureus, streptococci (except Enterococcus
faecalis), and susceptible anaerobes. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseBone and joint infections including acute hematogenous osteomyelitis caused by
Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic
bone and joint infections due to susceptible organisms. Launch Date8.6745596E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.92 ng/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.54 ng × h/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: Page: p.571 |
unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: Page: p.571 |
Disc. AE: Vaginal pain or burning... AEs leading to discontinuation/dose reduction: Vaginal pain or burning (1.2%) Sources: Page: p.571 |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Page: p.1Reaction skin (severe) Toxic epidermal necrolysis (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vaginal pain or burning | 1.2% Disc. AE |
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: Page: p.571 |
unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: Page: p.571 |
Anaphylactic shock | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Toxic epidermal necrolysis | grade 3-5 Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Reaction skin | severe Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 1.0 |
moderate [Inhibition 100 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
minor | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined |
PubMed
Title | Date | PubMed |
---|---|---|
Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. | 1999 Sep |
|
A simple, efficient and inexpensive program for preventing prematurity. | 2001 |
|
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary. | 2001 |
|
Streptococcal toxic shock syndrome revealed by a peritonitis. Case report and review of the literature. | 2001 |
|
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia. | 2001 Apr |
|
Severe babesiosis in Long Island: review of 34 cases and their complications. | 2001 Apr 15 |
|
Clindamycin suspension and endocarditis prophylaxis. | 2001 Apr 28 |
|
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections. | 2001 Feb |
|
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. | 2001 Feb |
|
[Microbiological and immunological monitoring in polyarticular rheumatoid arthritis after total joint replacement]. | 2001 Feb 9 |
|
[Guidelines for antibiotic prophylaxis of bacterial endocarditis in patients undergoing dental therapy]. | 2001 Jan |
|
The association of elevated percent bands on admission with failure and complications of interval appendectomy. | 2001 Jan |
|
Treatment of dogs infected with Hepatozoon americanum: 53 cases (1989-1998). | 2001 Jan 1 |
|
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat. | 2001 Jan 1 |
|
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. | 2001 Jan-Feb |
|
Cutaneous botryomycosis of the cervicofacial region. | 2001 Jul |
|
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. | 2001 Mar |
|
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis. | 2001 Mar |
|
Antibiotic-resistant bacteria in pediatric chronic sinusitis. | 2001 Mar |
|
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study. | 2001 Mar |
|
Sequential parapharyngeal abscesses. | 2001 Mar |
|
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada. | 2001 Mar |
|
Molecular epidemiology and genetic linkage of macrolide and aminoglycoside resistance in Staphylococcus intermedius of canine origin. | 2001 Mar 20 |
|
The treatment of babesiosis. | 2001 Mar 8 |
|
Effect of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in Babesia rodhaini-infected mice. | 2001 May |
|
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda. | 2001 May |
|
When to suspect and how to monitor babesiosis. | 2001 May 15 |
|
Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system. | 2017 Feb |
Sample Use Guides
150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD10AF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
CFR |
21 CFR 520.447
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
J01FF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-VATC |
QJ01FF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000175442
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
G01AA10
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
CFR |
21 CFR 520.446
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
D10AF51
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
LIVERTOX |
NBK548292
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000175442
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000175443
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-VATC |
QG01AA10
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
D10AF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
26988
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000009982
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NCI_THESAURUS |
C82922
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
27088
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-VATC |
QD10AF51
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3745
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
Clindamycin
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
2550
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
CLINDAMYCIN
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
m3624
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
3U02EL437C
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
DTXSID2022836
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
678
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
18323-44-9
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
C377
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
100000084276
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
SUB06665MIG
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
242-209-1
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
D002981
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
3U02EL437C
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL1753
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
446598
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
2582
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | RxNorm | ||
|
3037
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
DB01190
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
PARENT (METABOLITE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)